Panel Pushes For “Pragmatic” Post-Marketing Study, Head-To-Head Comparison For Forest’s Aclidinium
Executive Summary
FDA’s Pulmonary-Allergy Drugs Advisory Committee suggests including endpoints that will help determine the value added by the COPD drug. Forest Labs says it is ready to discuss post-marketing options with FDA.
You may also be interested in...
Tudorza’s Delivery System Key To Positioning For COPD Maintenance
Forest Laboratories’ sales representatives will combine marketing for aclidinium, which FDA approved July 24, with their education efforts for Daliresp for COPD exacerbations.
Forest’s Respiratory Pipeline: Can It Open The Revenue Airway?
At a June 20 analyst meeting, Forest Labs discussed the potential for its respiratory pipeline, including the recently launched Daliresp and the yet-to-be approved aclidinium, which has a July PDUFA date.
Forest’s Respiratory Pipeline: Can It Open The Revenue Airway?
At a June 20 analyst meeting, Forest Labs discussed the potential for its respiratory pipeline, including the recently launched Daliresp and the yet-to-be approved aclidinium, which has a July PDUFA date.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: